Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: Results of two open-label extension studies, CLEOPATRA-PD and PREFER

Journal of Neural Transmission

Volumn 120, Issue 7, 2013, Pages 1069-1081

  Lewitt, Peter A ^a,b   Boroojerdi, Babak ^c   Surmann, Erwin ^c   Poewe, Werner ^d  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCB PHARMA   (Belgium)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Clinical trial; Open label; Parkinson's disease; Rotigotine transdermal system

Indexed keywords

ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FALLING; FEMALE; HALLUCINATION; HEART INFARCTION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SHOCK; SIDE EFFECT; SOMNOLENCE; UROSEPSIS; COMPLICATION; CONTROLLED STUDY; INTRADERMAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TIME FACTORS;

EID: 84879550752     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0925-5     Document Type: Article

References (23)

1. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 8:929-937
2. Boroojerdi B, Wolff HM, Braun M, Scheller DK (2010) Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 46:483-505
3. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 investigators (2007) Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398-2404
4. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409-2417
5. Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044-1053
6. Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676-682
7. Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65(2 Suppl 1):3-5
8. LeWitt PA (2008) Levodopa for the treatment of Parkinson's disease. N Engl J Med 359:2468-2476
9. LeWitt P (2010) Dopaminergic agonists in Parkinson's disease. In: Kompoliti VM (ed) Encyclopedia of movement disorders. Academic press, Oxford, pp 332-336
10. LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68:1262-1267
11. Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 20:602-610
12. Nutt JG (2001) Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 8:101-108
13. Olanow CW, Obeso JA, Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2:382-392
14. Pahwa R, Poewe WH, Lyons KE, Boroojerdi B (2009) Changes in early morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD). Mov Disord 24(Suppl 1):S280
15. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284:1931-1938
16. Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 60:1721-1728
17. Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563-570
18. Pham DQ, Nogid A (2008) Rotigotine transdermal system for the treatment of Parkinson's disease. Clin Ther 30:813-824
19. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513-520
20. Rascol O, Perez-Lloret S (2009) Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 10:677-691
21. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491
22. Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90-99
23. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272-276